Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Complications of structural heart interventions

Complications of structural heart interventions are adverse events occurring during or after transcatheter procedures involving cardiac valves, septa and other cardiac structures. They include injury to vascular access sites and heart chambers, impaired valve function, interference with the cardiac conduction system, embolic events, infections and problems associated with implanted devices. The percutaneous approach reduces some of the effects of surgery but introduces specific interactions between native anatomy, instruments and prostheses. Assessing safety therefore requires knowledge both of the procedure and of the physiology it alters.

This field includes aortic valve implantation, mitral and tricuspid repair, selected valve replacements, closure of intracardiac communications and left atrial appendage occlusion. TAVI complications particularly reflect the relationship of the prosthesis to the annulus, outflow tract, coronary arteries and conduction tissue. With septal closure systems, by contrast, anchoring to defect rims, relationships with adjacent structures and changes in interatrial flow become especially important. These differences preclude applying a single risk frequency to all structural interventions.

Outcomes must be considered on three levels: technical success, haemodynamic correction and clinical benefit. A device may be deployed in the intended position without achieving adequate correction; satisfactory reduction of a defect may not translate into recovery for a patient with advanced myocardial or multiorgan damage. Conversely, a small residual finding may coexist with substantial benefit. Complication assessment must distinguish procedural events, device dysfunction and progression of the underlying disease.

Mechanisms of injury and determinants of risk

Mechanical trauma may occur anywhere along the path of the instruments: vascular access, aorta, septum, atrium, ventricle and valvular apparatus. Guidewire stiffness, delivery-system calibre and the force required to cross or anchor a device interact with calcification, tortuosity and tissue fragility. Laceration, dissection, perforation and bleeding may therefore originate far from the final target. The treatment site does not encompass all the anatomy that must be assessed before and during the intervention.

Anatomical interference results from the device's volume and position. A prosthesis may obstruct a coronary ostium or outflow tract, compress the conduction system or alter the movement of a neighbouring structure. An occluder may be unstable when the rims provide inadequate support or may exert harmful pressure on tissues. Sizing should not pursue immediate stability alone: oversizing can increase trauma and compression, whereas undersizing can favour migration and residual flow.

Implanted materials undergo a period of interaction with blood and biological integration. Surfaces not yet endothelialised, local stasis, inflammation and procoagulant conditions can promote thrombosis; microbial colonisation can cause device infection or endocarditis. Antithrombotic treatment reduces some risks but increases bleeding. This balance varies with implant type and site, atrial fibrillation, recent PCI and bleeding history, making a uniform regimen inappropriate across procedures.

The patient's physiological reserve affects tolerance of any event. Anaemia, renal failure, ventricular dysfunction, pulmonary hypertension, vascular disease and frailty can amplify the consequences of a technically limited complication. Frailty requires a functional and clinical assessment distinct from chronological age. Life expectancy, independence, cognitive status and rehabilitation potential also help determine what benefit is realistically attainable and what risk is proportionate.

Pathophysiology of correction and residual outcome

Removing a valvular obstruction or reducing regurgitation alters preload and afterload. After mitral correction, the left ventricle loses part of its ejection route into the low-pressure atrium and may reveal dysfunction previously masked by regurgitation. Following tricuspid correction, the right ventricle's ability to sustain the new ejection conditions becomes crucial. Early deterioration should not automatically be ascribed to device malfunction: haemodynamic adaptation, contractile injury and anatomical complications must be distinguished.

Closing an interatrial shunt redistributes volumes and may increase left ventricular filling. With reduced compliance, the communication may have served as a decompression route, and closure may promote pulmonary congestion. In patients with advanced pulmonary vascular disease, the interplay of pressures, shunt direction and resistance requires specialist assessment before intervention. Complete anatomical closure is not a safe goal in every pathophysiological setting.

Residual regurgitation can perpetuate volume overload and symptoms, whereas an excessive gradient may introduce a new obstruction. Post-TAVI paravalvular leak is flow outside the prosthetic leaflets and requires an assessment different from intraprosthetic regurgitation. In mitral repair, reduction in regurgitation and the residual orifice area must be considered together, because more aggressive correction can increase the gradient. A good outcome rests on balancing these effects.

Mechanical haemolysis may occur with high-velocity jets through small residual communications. The apparent size of a defect alone does not predict its haematological significance: geometry, turbulence and interactions with materials affect red-cell stress. Anaemia, increased lactate dehydrogenase, reduced haptoglobin and other consistent findings must be integrated with the clinical picture and imaging, while excluding blood loss and alternative causes.

Procedure types and characteristic complications

In aortic valve implantation, large-bore access, material embolisation, annular or outflow-tract injury, coronary obstruction, malposition and conduction disturbances are particularly relevant. Subsequent dysfunction may result from structural deterioration, non-structural problems, thrombosis or infection. Transcatheter valve thrombosis encompasses clinical presentations and imaging findings that do not all have the same significance. An increased gradient alone is insufficient to identify the cause.

Transcatheter mitral repair may be complicated by leaflet injury, incomplete insertion, single-leaflet device attachment loss, persistent or recurrent regurgitation and iatrogenic stenosis. Transseptal crossing adds a risk of perforation and residual communication. With mitral replacement systems, the relationship to the left ventricular outflow tract is essential to planning. Anatomy that permits device placement does not necessarily allow a durable and physiologically favourable result.

In tricuspid interventions, leaflet quality, coaptation gap, annular geometry, right ventricular function and any existing leads are important. The device may interfere with an existing lead or restrict its future management. Reduction in regurgitation may be incomplete, and the clinical response also depends on chronic congestion and hepatorenal injury. Repair and replacement outcomes should not be equated because anchoring, thrombotic risk and haemodynamic consequences differ.

Complications of atrial septal defect closure include migration or embolisation, erosion, thrombosis, arrhythmias and residual shunt, as well as the effects of redistributed volumes. In patent foramen ovale closure, the predominant aim is often to prevent another embolic event in selected patients, not to correct right-sided overload. PFO closure complications must therefore be interpreted in light of the appropriateness of the indication and the possibility of alternative stroke mechanisms.

Left atrial appendage occlusion may lead to pericardial effusion, device embolisation, surface thrombus and peri-device flow. A leak at this site is not equivalent to leakage around a valve prosthesis: the flows and consequences differ. Imaging surveillance and the antithrombotic strategy are integral to treatment. The possibility of limiting long-term anticoagulation does not eliminate the need to assess treatment required in the early phases and if device thrombosis occurs.

Vascular, bleeding and organ complications

Access-site complications include haematoma, pseudoaneurysm, arteriovenous fistula, dissection, rupture and limb ischaemia. Retroperitoneal bleeding may begin without an obvious groin haematoma, presenting with pain, hypotension or anaemia. Venous access and closure devices may also cause adverse events. Assessment should follow the route actually used and integrate pulses, perfusion, pain, blood pressure and haemoglobin, using ultrasound or vascular imaging when indicated.

Neurological injury may result from embolisation of thrombus, calcium, tissue or air, as well as hypoperfusion. A focal deficit requires immediate activation of the stroke pathway, establishing the time of onset and treatments received. Silent MRI-detected lesions and clinical stroke are different endpoints. Cerebral embolic protection should not be presented as a universal guarantee: indications and benefit depend on the evidence, procedure and device.

Acute kidney injury is often multifactorial. Contrast medium, hypotension, embolisation, haemolysis, congestion and medications may all contribute, especially in patients with reduced reserve. Prevention includes planning investigations, limiting unnecessary exposure, attending to haemodynamics and individualising fluid management. Attributing every increase in creatinine solely to contrast may conceal a correctable cause, such as low cardiac output or ongoing bleeding.

Respiratory and systemic complications include pulmonary oedema, aspiration, effects of sedation or anaesthesia, delirium and functional decline after hospitalisation. They are especially important in frail patients, in whom they can prolong admission despite a good cardiac result. Monitoring goes beyond echocardiography: mobilisation, nutrition, cognition and comorbidity management influence actual recovery.

Clinical presentation, history and physical examination

The timeline guides reasoning. Collapse during deployment suggests an immediate haemodynamic or mechanical complication; deterioration over the following hours may reflect bleeding, effusion, arrhythmia or ventricular adaptation; late symptoms raise the possibility of valve dysfunction, thrombosis, infection or progression of heart disease. These time windows are not exclusive: tamponade, atrioventricular block and embolisation may be delayed, and infection may also arise early.

The postprocedural history should establish device type and size, access, location, difficulties encountered, final imaging findings and prescribed treatment. Dyspnoea, syncope, fever, pain, palpitations and neurological symptoms are related to their onset and evolution. Distinguishing symptoms that never resolved from deterioration after a period of benefit is useful: the former may reflect incomplete correction or associated disease, whereas the latter heightens suspicion of a new event.

The physical examination includes blood pressure, heart rate, oxygen saturation, perfusion, congestion, auscultation, access sites and neurological assessment. A new murmur, signs of haemolysis or heart failure, asymmetric pulses and vascular swelling guide investigations. Fever and bacteraemia in a patient with intracardiac material warrant attention to endocarditis, without overlooking other infection sources. Assessment remains broad even when the procedure seems to offer an immediate explanation.

Investigations and diagnosis of complications

Transthoracic echocardiography is generally the first investigation of ventricular function, effusion, gradients and regurgitation. Comparison with baseline and post-implantation studies is decisive: a single measurement may be influenced by heart rate, flow, anaemia and loading conditions. Prosthesis assessment combines morphology and Doppler parameters, avoiding the diagnosis of obstruction merely because velocity appears high.

Transoesophageal echocardiography, including three-dimensional imaging, clarifies anchoring, position, leaflet motion, residual communications and possible vegetations. Intracardiac echocardiography can guide certain procedures and answer selected questions according to available expertise and devices. Method selection depends on the structure of interest and acoustic windows, as well as sedation risks and patient condition. Anatomical information must be related to haemodynamic consequences.

Cardiac computed tomography is central to planning many procedures and useful when thrombosis, malposition, obstruction or periprosthetic lesions are suspected. It can show leaflet thickening and reduced motion, but these findings require clinical interpretation. MRI may help quantify volumes and certain regurgitant flows where feasible; fluoroscopy and angiography retain roles in mechanical and vascular problems. Multimodal diagnosis is intended to resolve uncertainty, not to mandate every test for every patient.

ECG and monitoring identify conduction disturbances and arrhythmias. Blood count, renal function, haemolysis markers and biomarkers are requested according to suspicion. With possible endocarditis, blood cultures and imaging must be coordinated; in stable patients, cultures should precede antibiotics, without delaying treatment of unstable sepsis. PET/CT and other methods may contribute in selected cases under the relevant diagnostic criteria.

Defining the mechanism and classifying outcomes

Bioprosthetic dysfunction must be classified as structural deterioration, non-structural dysfunction, thrombosis or infection. Structural deterioration involves intrinsic, permanent changes, such as calcification or leaflet injury; prosthesis–patient mismatch or a leak has a different mechanism. Thrombosis may be reversible with appropriate therapy, whereas endocarditis requires an infectious-disease and structural management pathway. The distinction prevents interpreting every rising gradient as wear or every thickened leaflet as an automatic indication for reimplantation.

VARC-3 criteria provide standardised definitions for aortic valve research, including dysfunction, bleeding and other events. They support study comparisons but neither replace individual clinical judgement nor apply unchanged to every structural procedure. Device success, early safety, haemodynamic deterioration and bioprosthetic failure, in particular, measure different aspects. The outcome being described and the corresponding time interval must be specified.

Before reintervention, cause, reversibility and alternatives must be defined. Residual regurgitation may be technically correctable yet contribute little to symptoms; thrombosis may require medication before a new prosthesis is considered; infection may make additional implanted material inappropriate. Multidisciplinary discussion integrates anatomy, surgical risk, future coronary accessibility and the feasibility of further interventions, particularly for patients with long life expectancy.

Treatment of acute conditions and residual problems

In acute deterioration, the priority is to identify the mechanism while supporting circulation. Tamponade, vascular rupture, coronary obstruction, device embolisation and severe regurgitation require different solutions. Drainage, endovascular repair, percutaneous retrieval, revascularisation, a second device or surgery may be necessary depending on the problem. Successful rescue also depends on immediately available expertise, planned before the procedure starts.

Conduction disturbances require assessment of severity, persistence and progression risk. Advanced block may necessitate temporary pacing followed by a pacemaker, whereas other findings call for observation or prolonged monitoring. Decisions must reflect the electrocardiographic and procedural context: neither routine implantation nor discharge based on a single tracing is appropriate for all situations. Subsequent syncope requires reassessment of this risk.

For residual regurgitation, shunts and gradients, treatment depends on clinical relevance and the feasibility of correcting the mechanism. A small, stable abnormality may be followed, whereas heart failure, haemolysis, ischaemia or progression warrants discussion of reintervention. Expected benefit must outweigh risks of injuring structures, raising the gradient or compromising future access. Correcting an imaging finding is not an aim independent of physiology and the patient's trajectory.

Antithrombotic therapy and infection prevention

The antithrombotic strategy must reflect the particular procedure and concurrent indications. In the studied patients without an indication for chronic anticoagulation, POPular TAVI showed less bleeding with aspirin than with added clopidogrel. GALILEO, conversely, demonstrated an unfavourable balance for a rivaroxaban-based strategy in patients with no independent indication for anticoagulation after TAVI. These results support avoiding empirical intensification and do not justify extending the same regimen to septal occluders, appendage devices or other prostheses.

Documented thrombosis, atrial fibrillation or recent revascularisation changes management. Embolic risk, thrombus location, bleeding and treatment interactions are assessed with an explicit plan for duration and reassessment. Interruption for a later procedure must also be coordinated. Guidelines for appendage occlusion emphasise postprocedural assessment and management of thrombus and leak, while acknowledging uncertainties requiring individual decisions.

Infection prevention includes asepsis, appropriate periprocedural prophylaxis, management of active infections and oral hygiene. In patients with prosthetic valves and other defined high-risk groups, endocarditis prophylaxis recommendations apply to the relevant procedures. Following congenital heart disease repair with prosthetic material, duration and indications also depend on elapsed time and any residual defect. Merely having an intracardiac device does not justify antibiotics for every procedure.

Prevention, follow-up and prognosis

Prevention begins with indication and planning: confirming disease severity, anatomical measurements, access assessment, device selection and identifying potential rescue strategies. CT and echocardiography help estimate obstruction, anchoring and interference risks. In septal defects, pulmonary haemodynamics and left ventricular function may be as decisive as the communication's diameter. Heart Team discussion relates these findings to alternatives and patient goals.

Follow-up uses a reliable postprocedural reference and assessments proportionate to the procedure. New symptoms, gradient changes, anaemia, fever or arrhythmias require early reassessment. The programme must also be clear to clinicians caring for the patient outside the centre, with device identification, therapy, residual findings and investigation indications. Coordination between structural heart centres, community cardiology and other specialists helps recognise late events without turning surveillance into automatic testing.

Prognosis reflects the procedure, complications and pre-existing disease. COAPT data show that effective repair can provide sustained clinical benefits in selected patients with secondary mitral regurgitation; they do not show that every patient with advanced regurgitation benefits equally. In the initial TRILUMINATE Pivotal trial, the benefit of tricuspid repair was primarily related to quality of life over the assessed period. Population, follow-up duration and endpoint composition must be considered when communicating expected benefit.

Long-term consequences may include persistent heart failure, further hospitalisations, embolic events, haemolysis, infection and reintervention, as well as loss of independence after major complications. Good management considers survival, symptoms and function together. Structural interventions therefore remain longitudinal treatment: the procedure changes anatomy, while benefit depends on the stability of the result and ongoing care for heart disease and associated conditions.

References
  1. Praz F et al. 2025 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal. 2025;46(44):4635–4736.
  2. Généreux P et al. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. European Heart Journal. 2021;42(19):1825–1857.
  3. Zoghbi WA et al. Guidelines for the Evaluation of Prosthetic Valve Function With Cardiovascular Imaging: A Report From the American Society of Echocardiography Developed in Collaboration With the Society for Cardiovascular Magnetic Resonance and the Society of Cardiovascular Computed Tomography. Journal of the American Society of Echocardiography. 2024;37(1):2–63.
  4. Baumgartner H et al. 2020 ESC Guidelines for the management of adult congenital heart disease. European Heart Journal. 2021;42(6):563–645.
  5. Kavinsky CJ et al. SCAI Guidelines for the Management of Patent Foramen Ovale. Journal of the Society for Cardiovascular Angiography & Interventions. 2022;1(4):100039.
  6. Glikson M et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal. 2021;42(35):3427–3520.
  7. Delgado V et al. 2023 ESC Guidelines for the management of endocarditis. European Heart Journal. 2023;44(39):3948–4042.
  8. Goldsweig AM et al. 2025 SCAI/HRS Clinical Practice Guidelines on Transcatheter Left Atrial Appendage Occlusion. Journal of the Society for Cardiovascular Angiography & Interventions. 2025;4(9):103783.
  9. Brouwer J et al. Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. The New England Journal of Medicine. 2020;383(15):1447–1457.
  10. Dangas GD et al. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. The New England Journal of Medicine. 2020;382(2):120–129.
  11. Stone GW et al. Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation. The New England Journal of Medicine. 2023;388(22):2037–2048.
  12. Sorajja P et al. Transcatheter Repair for Patients with Tricuspid Regurgitation. The New England Journal of Medicine. 2023;388(20):1833–1842.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.